Short-term efficacy of oral verapamil in rest angina. A double-blind placebo controlled trial in CCU patients

The American Journal of Medicine
J MehtaC R Conti

Abstract

To determine the efficacy and safety of oral verapamil in patients with rest angina admitted to the Coronary Care Unit (CCU), a double-blind placebo-controlled trial was undertaken. Of the 65 patients with rest angina screened for the study, 15 met the inclusion criteria (at least two episodes of chest pain associated with ST-T segment changes per 24 hours) during single-blind placebo phase (Day 1). Patients were then randomized to receive either placebo or verapamil (80 mg every 6 hours) on Day 2. Protocol was designed such that those who did not respond to the placebo (nonresponders) received verapamil, 80 mg every 6 hours, whereas verapamil nonresponders received increased doses (120 mg every 6 hours) on Day 3. Those who did respond (responders) continued to receive their medication. Similar action was taken on Day 4, depending on chest pain frequency and clinical evaluation. The study drug was unblinded on Day 4. At the end of the four-day period, 13 patients were receiving verapamil (nine patients, 80 mg every 6 hours, and four patients, 120 mg every 6 hours) and all but one were responders. One patient received placebo all through the period of the study and was also considered to be a responder. In the remaining one pati...Continue Reading

Citations

Oct 1, 1990·Clinical Cardiology·R MulcahyM Fitzpatrick
May 1, 1992·Journal of Clinical Pharmacology·L M PrisantM J Frank
Jan 1, 1983·Pharmacology & Therapeutics·A G Ellrodt, B N Singh
Jan 1, 1983·Pharmacology & Therapeutics·W G Nayler, J D Horowitz
Mar 1, 1985·Journal of the American College of Cardiology·P ThérouxD D Waters
Oct 26, 1985·British Medical Journal·J Kenny
Nov 11, 1989·BMJ : British Medical Journal·P H HeldC D Furberg
Aug 1, 1985·Current Problems in Cardiology·D McCallR A O'Rourke
Jan 1, 1986·The Journal of Emergency Medicine·E BolgianoD Whye
Dec 2, 2006·Journal of Cardiothoracic and Vascular Anesthesia·Michael G FitzsimonsCharles Boucher
Apr 30, 1986·The American Journal of Medicine·S O Gottlieb, G Gerstenblith
Apr 1, 1985·The American Journal of Cardiology·F CreaA Maseri
Feb 2, 1999·The British Journal of Psychiatry : the Journal of Mental Science·F M QuitkinD F Klein
Jan 1, 1985·Urological Research·W G SimpsonJ I Harty
Jan 1, 1984·Medicinal Research Reviews·J R Guerrero, S S Martin
Mar 1, 1983·Drug Intelligence & Clinical Pharmacy·S S Martin, J R Guerrero
Sep 1, 1984·The Journal of Urology·W G SimpsonJ I Harty
Jan 1, 1986·Urological Research·R J BallouM T Tseng
Jun 1, 1987·Journal of Cardiac Surgery·C E Murphy, A S Wechsler
Sep 1, 1988·Cardiovascular Drugs and Therapy·C W Hamm, W Bleifeld

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.